PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg. - ppt download
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review - International Journal of Cardiology
Emerging Mechanisms in the Management of Heart Failure With Reduced Ejection Fraction
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V. - ppt video online download
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF | JACC: Heart Failure
Understanding the early mortality benefit observed in the PARADIGM-HF | VHRM
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure | Circulation
Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP
Neprilysin: Indications, Expectations, and Challenges | Revista Española de Cardiología
Emerging Mechanisms in the Management of Heart Failure With Reduced Ejection Fraction
Entresto Use in Heart Failure w Preserved Function – The Early Career Voice
New heart failure agent doubles mortality benefit of ACE inhibitors - PACE-CME
Trial Scorecard: PARADIGM-HF
PARADIGM-HF: A Concise Summary with Journal Club Questions - YouTube
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial - The Lancet Diabetes & Endocrinology
PARADISE MI Trial: Is Sacubitril/valsartan (Entresto) useful in patients with acute MI? – Visualmed
![PDF] Critical Questions about PARADIGM-HF and the Future. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/918ced0a75a7d84e5e8997682bb61d92ebedf17a/4-Figure2-1.png "PDF] Critical Questions about PARADIGM-HF and the Future. | Semantic Scholar")
PDF] Critical Questions about PARADIGM-HF and the Future. | Semantic Scholar
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis | JACC: Heart Failure
KoreaMed Synapse
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women - ScienceDirect
Frontiers | Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum
Use of Sacubitril/Valsartan in Heart Failure
